Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104
Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104
Active, not recruiting · NCT05841095 · Registry updated 2026-09-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104 | Blood-Borne Infections, Chronic Disease, DNA Virus Infections, Digestive System Diseases, Disease Attributes, Hepadnaviridae infectious disease, Hepatitis, Chronic, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic hepatitis B virus infection, hepatitis, hepatitis B virus infection, infectious disease, liver disorder, viral hepatitis, viral infectious disease | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-15 | NCT05841095 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Erasmus Medical Center | 271 |
| ISA Pharmaceuticals B.V. | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Erasmus MC | Rotterdam | Netherlands | 57 |